# US 2010/0304374 A1 · Methods and tools for discriminating colorectal adenomas and adenocarcinomas

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0304374 A1
- Document ID: US20100304374A1
- Status: Published application
- Kind: A1
- Application number: 12/594,490
- Filed: 2008-04-03
- Published: 2010-12-02
- Earliest claimed: 2007-04-05
- Assignees: Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg
- Inventors: Gerrit Albert Meijer; Beatriz Pinto Morais Carvalho
- Web page: https://patentgrep.com/patent/US20100304374A1

## CPC

- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to the differential expression of genes in colorectal adenoma and adenocarcinoma cells and their correlation with chromosomal aberrations. The present invention provides tools for detecting chromosomal aberrations linked to progression of adenomas into adenocarcinoma cells. The present invention discloses methods and tools for in vivo and in vitro diagnosis of colorectal tumours.

## Claims

### Claim 1

An in vitro method for detecting the presence of colorectal adenocarcinoma cells in a patient, the method comprising the steps of:
a) detecting in a test sample of said patient the expression level of at least the marker genes NM—017495 and NM—006602, and
b) comparing the expression level of said marker genes used in step a) to that of a control sample,
wherein an elevated expression level of said at least 2 marker genes in said test sample, compared to said control sample, is indicative of the presence of colorectal adenocarcinoma cells in said patient.

### Claim 2 (depends on 1)

An in vitro method according to claim 1 comprising the steps of:
a) detecting in a test sample of said patient the expression level of at least the marker genes NM—017495, NM—006602, NM—018840, NM—003600, NM—018270, NM—007002 and NM—016397, and
b) comparing the expression level of said marker genes used in step a) to that of a control sample,
wherein an elevated expression level of said at least 7 marker genes in said test sample, compared to said control sample, is indicative of the presence of colorectal adenocarcinoma cells in said patient.

### Claim 3

An in vitro method for detecting the presence of colorectal adenocarcinoma cells in a patient, the method comprising the steps of:
a) detecting in a test sample of said patient the expression level of at least 12 of the marker genes, selected from the group listed in Table 1, and
b) comparing the expression level of the marker genes used in step a) to that of a control sample,
wherein an elevated or decreased expression level of said at least 12 marker genes in said test sample, compared to said control sample, is indicative of the presence of colorectal adenocarcinoma cells in said patient.

### Claim 4

An in vitro method for detecting the presence of colorectal adenocarcinoma cells in a patient, the method comprising the steps of:
a) detecting in a test sample of said patient the expression level of one or more marker genes, selected from the group listed in Table 17, and
b) comparing the expression level of said at least one marker gene used in step (a) to that of a control,
wherein an elevated or decreased expression level of said one or more marker genes in said test sample, compared to said control sample, is indicative of the presence of colorectal adenocarcinoma cells in said patient.

### Claim 5

An in vitro method for detecting the presence of colorectal adenocarcinoma cells in a patient, the method comprising the steps of:
a) detecting in a test sample of said patient the expression level of one or more marker genes, the expression of which is altered upon the presence of a chromosomal aberration, wherein said one or marker genes comprise:
two or more marker genes selected from the group of marker genes depicted in Table 2 of which the expression level is altered by chromosomal loss at chromosome 8p and/or,
one or more marker genes selected from the group of marker genes depicted in Table 3 of which the expression level is altered by chromosomal gain at chromosome 8q and/or,
three or more marker genes selected from the group of marker genes depicted in Table 4 of which the expression level is altered by chromosomal gain at chromosome 13q, and/or
one or more marker genes selected from the group of marker genes depicted in Table 5 of which the expression level is altered by chromosomal loss at chromosome 15q, and/or
one or more marker genes selected from the group of marker genes depicted in Table 6 of which the expression level is altered by chromosomal loss at chromosome 17p and/or,
three or more marker genes selected from the group of marker genes depicted in Table 7 of which the expression level is altered by chromosomal loss at chromosome 18q and/or,
nine or more marker genes selected from the group of marker genes depicted in Table 8 of which the expression level is altered by chromosomal gain at chromosome 20q, and/or
two or more marker genes selected from the group of marker genes depicted in Table 9 of which the expression level is altered by chromosomal gain at chromosome 20q; and
b) comparing the expression level of the one or more marker genes used in step (a) to that of control sample(s);
wherein an elevated or decreased expression level of said one or more marker genes in said test sample, compared to the control sample, is indicative of the presence of adenocarcinoma cells in said patient.

### Claim 6

An in vitro method for detecting the presence of colorectal adenocarcinoma cells in a patient, the method comprising the steps of:
a) detecting in a test sample of said patient the expression level of a plurality of marker genes the expression of which is altered upon the presence of a chromosomal aberration, said plurality of marker genes comprising:
at least one marker gene of which the expression level is altered by chromosomal loss at chromosome 8p, selected from the group of marker genes depicted in Table 2, and
at least one marker gene of which the expression level is altered by chromosomal gain at chromosome 8q, selected from the group of marker genes depicted in Table 3, and
at least one marker gene of which the expression level is altered by chromosomal gain at chromosome 13, selected from the group of marker genes depicted in Table 4, and
at least one marker gene of which the expression level is altered by chromosomal loss at chromosome 15q, selected from the group of marker genes depicted in Table 5, and
at least one marker gene of which the expression level is altered by chromosomal loss at chromosome 17p, selected from the group of marker genes depicted in Table 6, and
at least one marker gene of which the expression level is altered by chromosomal loss at chromosome 18q, selected from the group of marker genes depicted in Table 7, and
at least one marker gene of which the expression level is altered by chromosomal gain at chromosome 20q, selected from the group of marker genes depicted in Table 8 or in Table 9; and
b) comparing the expression level of the marker genes used in step a) to that of a control sample,
wherein an elevated or decreased expression level of said plurality of markers in said test sample, compared to the control sample, is indicative of the presence of adenocarcinoma cells in said patient.

### Claim 7 (depends on 3)

The method according to claim 3 wherein said marker genes have a p or FDR value below 0.05 in accordance with Tables 1 to 9.

### Claim 8 (depends on 3)

The method according to claim 3, wherein said marker genes have a p or FDR value below 0.01, in accordance with Tables 1 to 9.

### Claim 9 (depends on 3)

The method according to claim 3, wherein said marker genes have a difference in expression level of at least ‘2’ between an adenoma and an adenocarcinoma cell, in accordance with Tables 2 to 9.

### Claim 10 (depends on 3)

The method according to claim 3, wherein said marker genes have a difference in expression level of at least ‘4’ between an adenoma and an adenocarcinoma cell in accordance with Tables 2 to 9.

### Claim 11 (depends on 5)

The method according to claim 5, wherein the marker genes, the expression level of which is altered by a chromosomal loss at chromosome 8p, are selected from the group of marker genes consisting of NM—020749, NM—004315, NM—003747, NM—016353, NM—152415, NM—006197, NM—000662, NM—000015, D31887, NM—017884, NM—004462, NM—006765, NM—001715, NM—012331, NM—139167, NM—013354 and NM—005144.

### Claim 12 (depends on 5)

The method according to claim 5 wherein the marker genes, the expression level of which is altered by a chromosomal gain at chromosome 8q, are selected from the group of marker genes consisting of NM—138455, NM—032611, NM—032862, AL713790, BC030520, NM—024035, NM—017767, NM—002346, AF289596, NM—012162 and AB051475.

### Claim 13 (depends on 5)

The method according to claim 5, wherein the marker genes, the expression level of which is altered by a chromosomal gain at chromosome 13q, are selected from the group of marker genes consisting of NM—145293, NM—005358, U50531, NM—012158, NM—017817, NM—003899, NM—003903, NM—018386, BC008975, NM—023011, NM—001260, NM—006646, U50524, NM—033111, NM—024808, NM—014832, NM—006002, NM—015057, NM—024546, BC026126, NM—006493, NM—018210 and NM—017664.

### Claim 14 (depends on 5)

The method according to claim 5, wherein the marker genes the expression level of which is altered by a chromosomal loss at chromosome 15q, are selected from the group of marker genes consisting of NM—030574, NM—004255, NM—002573, AB033025, NM—033240, NM—000126, NM—015079, NM—015969 and NM—016073.

### Claim 15 (depends on 5)

The method according to claim 5, wherein the marker genes, the expression level of which is altered by a chromosomal loss at chromosome 17p, are selected from the group of marker genes consisting of NM—130766, NM—015721 and NM—031430.

### Claim 16 (depends on 5)

The method according to claim 5, wherein the marker genes, the expression level of which is altered by a chromosomal loss at chromosome 18q, are selected from the group of marker genes consisting of NM—004715, NM—006701 and NM—014913.

### Claim 17 (depends on 5)

The method according to claim 5 wherein the marker genes, the expression level of which is altered by a chromosomal gain at chromosome 20q, are selected from the group of marker genes consisting of NM—016397, NM—018270, NM—006602, NM—080476, NM—017896, NM—006097, NM—021809, NM—018840, NM—003600, NM—017495, NM—007002, NM—016354, NM—014071, NM—002212, NM—003185, NM—152255, NM—022082, NM—018244, NM—014902, NM—032013, NM—020182, NM—006886, NM—020673, BC003122, NM—012325, NM—014183, NM—021100, NM—004738, NM—016045, NM—014054, NM—022105, NM—015666, NM—032527, BC025345, NM—033405, NM—006892, NM—005225, NM—000687, BC035639, NM—018677, NM—006047, NM—016436, NM—015511, NM—016082, NM—007238, NM—003908, NM—003610, NM—153360, NM—080425, NM—000114, NM—001853, NM—144498, NM—017798 and NM—012384.

### Claim 18 (depends on 5)

The method according to claim 5, wherein the marker genes the expression level of which is altered by a chromosomal gain at chromosome 20q are selected from the group of marker genes consisting of NM—016397, NM—018270, NM—006602, NM—080476, NM—017896, NM—006097, NM—021809, NM—018840, NM—003600, NM—017495, NM—007002, NM—016354, NM—014071, NM—002212, NM—003185, NM—152255, NM—022082, NM—018244, NM—014902, NM—032013, NM—020182, NM—006886, NM—020673, BC003122, NM—012325, NM—014183, NM—021100, NM—004738, NM—016045, NM—014054, NM—022105, NM—015666, NM—032527, BC025345 and NM—033405.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the test sample is a biopsy or resection of colorectal adenoma tissue.

### Claim 20 (depends on 1)

The method according to claim 1, wherein the test sample is selected from the group consisting of a sample of urine, blood, saliva, sweat and stool.

### Claim at position 21

21-42. (canceled)
